Hematologic Malignancy
Lymphoid Leukemia
CI-CAN-00001101Explore in graph →
Hematologic827 active trials20 approved drugs95 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001101Explore in graph →
Clinical trials
3,262 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (489)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01643668 | Busulfan/Clofarabine + Allogeneic Stem Cell Transplantation | completed | Phase 2 | 34 | Massachusetts General HospitalOTHER | 1 | Jul 13, 2017 | clinicaltrials |
| NCT00058240 | Flavopiridol in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma | completed | Phase 1 / Phase 2 | 52 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2017 | clinicaltrials |
| NCT00496132 | A Trial of the Safety of Escalating Doses of PRO131921 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia | terminated | Phase 1 / Phase 2 | 16 | Genentech, Inc.INDUSTRY | 0 | Jul 2, 2017 | clinicaltrials |
| NCT01167166 | Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL) | completed | Phase 1 / Phase 2 | 30 | Traws Pharma, Inc.INDUSTRY | 1 | Jun 26, 2017 | clinicaltrials |
| NCT03166878 | A Study Evaluating UCART019 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma | unknown | Phase 1 / Phase 2 | 80 | Chinese PLA General HospitalOTHER | 1 | Jun 23, 2017 | clinicaltrials |
| NCT03191773 | A Study of Anti-CD19 CAR-T Cell Immunotherapy for Refractory /Relapsed B Cell Malignancies | unknown | Phase 1 / Phase 2 | 100 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 20, 2017 | clinicaltrials |
| NCT00145626 | HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies | completed | Phase 2 | 40 | St. Jude Children's Research HospitalOTHER | 1 | Jun 19, 2017 | clinicaltrials |
| NCT02660762 | Modified MRCUKALLⅫ/ECOGE2993 Regimen for ALL | unknown | Phase 2 | 100 | Sun Yat-sen UniversityOTHER | 1 | Jun 19, 2017 | clinicaltrials |
| NCT00241358 | Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies | completed | Phase 1 / Phase 2 | 92 | Washington University School of MedicineOTHER | 1 | Jun 6, 2017 | clinicaltrials |
| NCT01848145 | Rapid Infusion of Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia | completed | Phase 2 | 34 | SCRI Development Innovations, LLCOTHER | 1 | Jun 6, 2017 | clinicaltrials |
| NCT01466153 | A Phase 2, Multicenter, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) | completed | Phase 2 | 183 | MedImmune LLCINDUSTRY | 8 | May 31, 2017 | clinicaltrials |
| NCT00118352 | Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer | completed | Phase 2 | 12 | Fred Hutchinson Cancer CenterOTHER | 2 | May 30, 2017 | clinicaltrials |
| NCT02259348 | Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation | terminated | Phase 2 | 12 | St. Jude Children's Research HospitalOTHER | 1 | May 30, 2017 | clinicaltrials |
| NCT00795769 | Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant | completed | Phase 2 | 49 | Fred Hutchinson Cancer CenterOTHER | 1 | May 23, 2017 | clinicaltrials |
| NCT01486797 | NOX-A12 in Combination With Bendamustine and Rituximab in Relapsed Chronic Lymphocytic Leukemia (CLL) | completed | Phase 2 | 28 | TME Pharma AGINDUSTRY | 4 | May 22, 2017 | clinicaltrials |
| NCT01427881 | Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies | completed | Phase 2 | 43 | Fred Hutchinson Cancer CenterOTHER | 1 | May 19, 2017 | clinicaltrials |
| NCT01011894 | Lenalidomide in Patients With Chronic Lymphocytic Leukemia Older Than 65 Years of Age | completed | Phase 2 | 26 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 18, 2017 | clinicaltrials |
| NCT00049504 | Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer | completed | Phase 2 | 53 | Fred Hutchinson Cancer CenterOTHER | 1 | May 17, 2017 | clinicaltrials |
| NCT01133743 | Open-Label Study of Lenalidomide in Combination With Oral Dexamethasone in the Treatment of Previously Untreated, Symptomatic Patients With Chronic Lymphocytic Leukemia | completed | Phase 2 | 31 | University Health Network, TorontoOTHER | 1 | May 3, 2017 | clinicaltrials |
| NCT02371577 | Evaluation of the Immune Restoration Potential Of Lenalidomide(Revlimid) | withdrawn | Phase 2 | 0 | University of California, San DiegoOTHER | 1 | Apr 28, 2017 | clinicaltrials |
| NCT02963038 | CAR T Cells for Refractory B Cell Malignancy | unknown | Phase 1 / Phase 2 | 10 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | Apr 28, 2017 | clinicaltrials |
| NCT01414205 | A Study Comparing Obinutuzumab (RO5072759; GA101) 1000 Milligram (mg) Versus 2000 mg in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (GAGE) | completed | Phase 2 | 80 | Genentech, Inc.INDUSTRY | 1 | Apr 17, 2017 | clinicaltrials |
| NCT01868893 | An Expanded Access, Open-Label Study of Obinutuzumab (GA101) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia | completed | Phase 2 | 20 | Genentech, Inc.INDUSTRY | 1 | Apr 17, 2017 | clinicaltrials |
| NCT01173679 | Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory CLL and SLL | terminated | Phase 2 | 10 | Massachusetts General HospitalOTHER | 1 | Apr 14, 2017 | clinicaltrials |
| NCT01363297 | Study Evaluating Inotuzumab Ozogamicin In Acute Lymphocytic Leukemia | completed | Phase 2 | 72 | PfizerINDUSTRY | 1 | Apr 13, 2017 | clinicaltrials |
| NCT00596336 | Study of Immune Responses to Influenza Vaccination With or Without Imiquimod Application in Untreated CLL Patients(CLLIFVAC) | terminated | Phase 2 | 24 | The Royal Bournemouth HospitalOTHER | 1 | Apr 12, 2017 | clinicaltrials |
| NCT02973191 | A Study to Determine Safety, Feasibility and Efficacy of JCAR015 in Adult Subjects With B-Cell Acute Lymphoblastic Leukemia(ORBIT) | withdrawn | Phase 1 / Phase 2 | 0 | CelgeneINDUSTRY | 7 | Apr 10, 2017 | clinicaltrials |
| NCT02200380 | A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs | terminated | Phase 2 | 36 | Celldex TherapeuticsINDUSTRY | 1 | Apr 7, 2017 | clinicaltrials |
| NCT00636909 | Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders(MINI HEME) | completed | Phase 2 | 25 | Beth Israel Deaconess Medical CenterOTHER | 0 | Apr 6, 2017 | clinicaltrials |
| NCT02227108 | Study in Pediatrics With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma | terminated | Phase 2 | 37 | MedImmune LLCINDUSTRY | 8 | Apr 6, 2017 | clinicaltrials |
| NCT00091559 | Oral SAHA (Suberoylanilide Hydroxamic Acid) in Advanced Cutaneous T-cell Lymphoma (0683-001) | completed | Phase 2 | 74 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 5, 2017 | clinicaltrials |
| NCT00360776 | Tipifarnib in Treating Patients With Anemia or Neutropenia and Large Granular Lymphocyte Leukemia | terminated | Phase 2 | 25 | National Cancer Institute (NCI)NIH | 1 | Apr 5, 2017 | clinicaltrials |
| NCT01396070 | Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression Level | completed | Phase 2 | 36 | Youn KimOTHER | 1 | Apr 5, 2017 | clinicaltrials |
| NCT00973752 | Treatment of Older Adults With Acute Lymphoblastic Leukemia | completed | Phase 2 | 30 | Massachusetts General HospitalOTHER | 1 | Mar 30, 2017 | clinicaltrials |
| NCT00052520 | Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation | completed | Phase 1 / Phase 2 | 37 | Fred Hutchinson Cancer CenterOTHER | 1 | Mar 29, 2017 | clinicaltrials |
| NCT02685670 | Competitive Transfer of αCD19-TCRz-CD28 and αCD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/Lymphoma(MatchCART) | unknown | Phase 1 / Phase 2 | 20 | The Second Affiliated Hospital of Henan University of Traditional Chinese MedicineOTHER | 1 | Mar 16, 2017 | clinicaltrials |
| NCT01944943 | Phase II Study of Vismodegib in Patients With Refractory or Relapsed B-cell Lymphoma or Chronic Lymphocytic Leukemia(VISMOLY) | terminated | Phase 2 | 31 | The Lymphoma Academic Research OrganisationOTHER | 1 | Mar 13, 2017 | clinicaltrials |
| NCT01181271 | Tandem Auto-Allo Transplant for Lymphoma | completed | Phase 2 | 42 | Massachusetts General HospitalOTHER | 1 | Mar 9, 2017 | clinicaltrials |
| NCT00143845 | Study of Low-Intensity Conditioning for Allogeneic Stem Cell Transplant | completed | Phase 2 | 54 | University of Michigan Rogel Cancer CenterOTHER | 1 | Mar 8, 2017 | clinicaltrials |
| NCT01209286 | Study of the BiTE® Blinatumomab (MT103) in Adult Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL) | completed | Phase 2 | 36 | Amgen Research (Munich) GmbHINDUSTRY | 1 | Mar 6, 2017 | clinicaltrials |
| NCT01621477 | T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant | terminated | Phase 2 | 34 | St. Jude Children's Research HospitalOTHER | 1 | Feb 20, 2017 | clinicaltrials |
| NCT01475058 | CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant | completed | Phase 1 / Phase 2 | 1 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 15, 2017 | clinicaltrials |
| NCT02167360 | Study of Efficacy and Safety of CTL019 in Adult ALL Patients | withdrawn | Phase 2 | 0 | Abramson Cancer Center at Penn MedicineOTHER | 0 | Feb 14, 2017 | clinicaltrials |
| NCT00460694 | Allogeneic Cytokine-induced Killer Immunotherapy for Relapse After Allogeneic Marrow Transplant for Haematological Malignancies(alloCIK) | completed | Phase 1 / Phase 2 | 24 | Singapore General HospitalOTHER | 1 | Feb 10, 2017 | clinicaltrials |
| NCT00143065 | Fludarabine, Rituximab, and Alemtuzumab for B-Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | completed | Phase 2 | 8 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Feb 8, 2017 | clinicaltrials |
| NCT00201682 | Etanercept and Rituximab in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma | completed | Phase 1 / Phase 2 | 36 | John ByrdOTHER | 1 | Feb 8, 2017 | clinicaltrials |
| NCT01471782 | Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia | completed | Phase 1 / Phase 2 | 93 | Amgen Research (Munich) GmbHINDUSTRY | 7 | Feb 8, 2017 | clinicaltrials |
| NCT02042911 | Efficacy and Safety Study of SyB L-0501 for Patients With Chronic Lymphocytic Leukemia | completed | Phase 2 | 10 | SymBio PharmaceuticalsINDUSTRY | 1 | Feb 1, 2017 | clinicaltrials |
Data updated 23 days agoSource updated Jul 13, 2017source: clinicaltrials